Novel anti-fungal agents from cryptic microbial metabolites
Introducing a groundbreaking approach to discover novel anti-fungal agents from cryptic microbial metabolites, targeting rice blast disease. Utilizing proprietary methods, we access unique bioactive compounds previously inaccessible by conventional means.
Overview
This innovative solution leverages a proprietary method to uncover novel anti-fungal agents derived from cryptic microbial metabolites. These metabolites, encoded by transcriptionally silent biosynthetic genes, remain untapped by traditional discovery techniques. Through this approach, thousands of new bioactive natural products have been identified. The focus is on targeting rice blast disease, a major threat to global agriculture, by screening a curated library of novel compounds against the causative pathogen, P. oryzae.
Technical specifications
Key features:
- Access to a vast library of over 200 novel natural products, uniquely identified through proprietary technology.
- Specialized screening methods to evaluate compounds against rice blast disease.
- Utilization of dose-response assays to determine the half-maximal inhibitory concentrations of promising candidates.
- Potential to expand screening to a larger library of natural product mixtures if initial hits are not observed.
- Advanced techniques for activity-guided fractionation, isolation, and structure elucidation to characterize effective agents.
Technology readiness level
Currently at Technology Readiness Level 5, this solution has progressed to preclinical development stages with ongoing validation efforts. The proprietary approach has already yielded novel antibiotics and anti-fungal agents, demonstrating significant potential for agricultural applications.
About Princeton University
Princeton University is a private, research-intensive university in Princeton, New Jersey, known for a tightly integrated campus and a globally connected research enterprise. Industry partners engage through a dedicated corporate relations team that brokers sponsored research, consortia, and talent pipelines. Co-located assets include shared user facilities for advanced imaging and nanofabrication, a university-managed U.S. Department of Energy national lab, and a research park that hosts corporate collaborators. Research is supported by competitive federal funding from agencies such as NSF, NIH, DOE, DoD, and NASA. A technology transfer office provides IP strategy, licensing, and startup support, complemented by an affiliated incubator and mentor network.
delivered to your inbox.